A quinoxaline-type tyrphostin that acts as a potent and selective inhibitor of PDGF receptor kinase in vitro and in Swiss 3T3 cells (IC<sub>50</sub>s range from 0.3-1 µM) inhibits PDGF-stimulated DNA synthesis (IC<sub>50</sub> = 2.
A quinoxaline-type tyrphostin that acts as a potent and selective inhibitor of PDGF receptor kinase in vitro and in Swiss 3T3 cells (IC<sub>50</sub>s range from 0.3-1 µM) inhibits PDGF-stimulated DNA synthesis (IC<sub>50</sub> = 2.
A potent CCKB/gastrin receptor antagonist that exhibits selective binding for CCKB compared to CCKA exhibits synergistic inhibitory effects on the cell viability of human gastric cancer cells when administered in combination with the selective
A potent CCKB/gastrin receptor antagonist that exhibits selective binding for CCKB compared to CCKA exhibits synergistic inhibitory effects on the cell viability of human gastric cancer cells when administered in combination with the selective
A tyrphostin that is a poor inhibitor of EGFRK (IC<sub>50</sub> = 450 &muM) and PDGFRK (IC<sub>50</sub> > 100 &muM) which has been found to inhibit the phosphorylation of ERK1 and ERK2 at 25-50 &muM blocks the production of TNF-&alpha,
A tyrphostin that is a poor inhibitor of EGFRK (IC<sub>50</sub> = 450 &muM) and PDGFRK (IC<sub>50</sub> > 100 &muM) which has been found to inhibit the phosphorylation of ERK1 and ERK2 at 25-50 &muM blocks the production of TNF-&alpha,
An inactive control to be used in experiments with AGK2 has IC<sub>50</sub> values greater than 50 µM on SIRT1 and SIRT2 and greater than 5 µM on SIRT3.
An inactive control to be used in experiments with AGK2 has IC<sub>50</sub> values greater than 50 µM on SIRT1 and SIRT2 and greater than 5 µM on SIRT3.
A potent CCKB/gastrin receptor antagonist that exhibits selective binding for CCKB compared to CCKA exhibits synergistic inhibitory effects on the cell viability of human gastric cancer cells when administered in combination with the selective
A potent CCKB/gastrin receptor antagonist that exhibits selective binding for CCKB compared to CCKA exhibits synergistic inhibitory effects on the cell viability of human gastric cancer cells when administered in combination with the selective